A source-backed research page for trial rows and update notes connected to this compound or investigational product. The page is generated from the Notion tracker and should be read as a living research map, not a medical conclusion.
Trial registration, company topline, CNPV/rolling-review status, recruitment status, public-dashboard data, or review literature do not equal approval, label, reimbursement, access, safety, or efficacy. Check each source note before turning a row into a claim.
This page links out to registry/source records, the global trial tracker, the updates feed, and matching wiki dossiers when available.
ClinicalTrials.gov manual verification on 2026-04-17 | Overall status: RECRUITING | Exact phase: Not Applicable | Lead sponsor: University of Sao Paulo | Conditions: Healthy Women Volunteers | Interventions: Ayahuasca; Esketamine
ClinicalTrials.gov manual verification on 2026-04-17 | Overall status: RECRUITING | Exact phase: Not Applicable | Lead sponsor: University of Sao Paulo | Conditions: Healthy Women Volunteers | Interventions: Ayahuasca; Esketamine
ClinicalTrials.gov manual verification on 2026-04-17 | Overall status: RECRUITING | Exact phase: Phase 2 | Lead sponsor: University of Sao Paulo | Conditions: Posttraumatic Stress Disorder (PTSD) | Interventions: Ayahuasca; Esketamine
ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: University of Sao Paulo | Official title: Four Doses of Ayahuasca or Esketamine in Major Depressive Disorder: a Double-blind Randomized Trial | Condition: Major Depression Severe | Intervention: Ayahuasca; Esketamine | Study type: Interventional | Comparator intervention also includes esketamine, so this row is tagged to both Ayahuasca and Ketamine.
ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: COMPLETED | Exact phase: Phase 1/Phase 2 | Lead sponsor: Universidade Federal do Rio Grande do Norte | Conditions: Major Depression | Interventions: Ayahuasca; placebo
ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine | Interventions: N,N-dimethyltryptamine (DMT) + harmine; Placebo
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: UNKNOWN | Exact phase: Phase 2 | Lead sponsor: Beckley Med Foundation | Conditions: Bereavement
ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: COMPLETED | Exact phase: PHASE1 | Lead sponsor: Reconnect Labs | Conditions: Healthy | Interventions: Dimethyltryptamin (DMT) & Harmine | Notes: DMT + harmine combination tagged as Ayahuasca, DMT because the registry explicitly lists both ayahuasca-relevant constituents.
ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: COMPLETED | Exact phase: Early Phase 1 | Lead sponsor: Milan Scheidegger | Conditions: Healthy Participants | Interventions: DMT + harmine; Placebo | Notes: Summary explicitly frames Ayahuasca as the relevant plant preparation context.
ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: UNKNOWN | Exact phase: Phase 1 | Lead sponsor: Advanced Integrative Medical Science Institute | Conditions: Major Depression; Post Traumatic Stress Disorder | Interventions: SM-001 | Notes: Brief summary describes SM-001 as a standardized Ayahuasca analog. Tracker status mapped to Active because UNKNOWN is not an available status option.
ClinicalTrials.gov v2 sync on 2026-04-18 | Overall status: COMPLETED | Exact phase: EARLY_PHASE1 | Lead sponsor: Psychiatric University Hospital, Zurich | Conditions: Emotions; Mood; Cognitive Function 1, Social; Empathy | Interventions: DMT; Harmine; Placebo (Harmine); Placebo (DMT) | Notes: DMT + harmine combination tagged as Ayahuasca, DMT because the registry explicitly lists both ayahuasca-relevant constituents.
PubMed PMID 42100741 / iScience evaluates whether machine-learning models on dried-leaf images can recover folk classifications of Banisteriopsis caapi, the ayahuasca vine; reported SVM overall accuracy reached about 70%, with higher accuracy for some folk types and lower accuracy where morphology overlaps.
Last checked 2026-05-15 UTC. Claim boundary: ethnobotany/classification and wiki/source-map item only; not clinical evidence about ayahuasca effects, safety, efficacy, legal access, or medical use.
PubMed PMID 42104189 / Clinical Pharmacology & Therapeutics scoping review identifies 26 eligible registered interventional trials of DMT, ayahuasca, and DMT plus harmine on ClinicalTrials.gov. Review says the registry landscape expanded after 2020–2021 and remains dominated by early-stage safety/physiological and subjective-effect characterization, with disorder-specific symptom endpoints less often primary.
Last checked 2026-05-15 UTC. Claim boundary: review/registry-map item only; supports wiki/trial-landscape context, not clinical efficacy/safety conclusion, approval, label, reimbursement, or access.